Drugs / N-DESETHYLOXYBUTYNIN
N-DESETHYLOXYBUTYNIN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03402152 | Nov 2018 → Jan 2021 | bipolar depression | NeuroRx, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-DESETHYLOXYBUTYNIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544785 ↗ |
| Known as | NRX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03402152 ↗ |
| Known as | NT-0502 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544785 ↗ |
| Modality | Small molecule | — CHEMBL3544785 ↗ |
| Route | Oral | “will be given twice a day by mouth” NCT03402152 ↗ |